| 1 |
The HDAC6-selective inhibitor is effective against non-Hodgkin lymphoma and synergizes with ibrutinib in follicular lymphoma.Mol Carcinog. 2019 Jun;58(6):944-956. doi: 10.1002/mc.22983. Epub 2019 Feb 27.
|
| 2 |
Relevance of ID3-TCF3-CCND3 pathway mutations in pediatric aggressive B-cell lymphoma treated according to the non-Hodgkin Lymphoma Berlin-Frankfurt-Mnster protocols.Haematologica. 2017 Jun;102(6):1091-1098. doi: 10.3324/haematol.2016.156885. Epub 2017 Feb 16.
|
| 3 |
Preclinical evaluation of a diabody-based (177)Lu-radioimmunoconjugate for CD22-directed radioimmunotherapy in a non-Hodgkin lymphoma mouse model.Cancer Lett. 2016 Oct 28;381(2):296-304. doi: 10.1016/j.canlet.2016.08.007. Epub 2016 Aug 11.
|
| 4 |
Investigational therapies targeting CD37 for the treatment of B-cell lymphoid malignancies.Expert Opin Investig Drugs. 2018 Feb;27(2):171-177. doi: 10.1080/13543784.2018.1427730. Epub 2018 Jan 15.
|
| 5 |
Genetic variations in xenobiotic metabolic pathway genes, personal hair dye use, and risk of non-Hodgkin lymphoma.Am J Epidemiol. 2009 Nov 15;170(10):1222-30. doi: 10.1093/aje/kwp263. Epub 2009 Oct 12.
|
| 6 |
The 3D Genome: EZH2 Comes into the Fold.Trends Mol Med. 2019 May;25(5):362-365. doi: 10.1016/j.molmed.2019.02.013. Epub 2019 Mar 15.
|
| 7 |
Fibroblast growth factor receptor 4 polymorphism is associated with increased risk and poor prognosis of non-Hodgkin's lymphoma.Tumour Biol. 2014 Apr;35(4):2997-3002. doi: 10.1007/s13277-013-1386-7. Epub 2013 Nov 19.
|
| 8 |
Level of PAX5 in differential diagnosis of non-Hodgkin's lymphoma.Indian J Med Res. 2016 May;143(Supplement):S23-S31. doi: 10.4103/0971-5916.191747.
|
| 9 |
Association of aberrant transcortin levels with HLA antigens of the B and C loci: high transcortin levels are frequently found in patients with lymphatic leukemia, hairy cell leukemia, or non-Hodgkin lymphoma.J Clin Endocrinol Metab. 1980 Oct;51(4):868-72. doi: 10.1210/jcem-51-4-868.
|
| 10 |
CXCR5 polymorphisms in non-Hodgkin lymphoma risk and prognosis.Cancer Immunol Immunother. 2013 Sep;62(9):1475-84. doi: 10.1007/s00262-013-1452-4. Epub 2013 Jun 28.
|
| 11 |
Association between polymorphic sites in thymidylate synthase gene and risk of non-Hodgkin lymphoma: a systematic review and pooled analysis.Leuk Lymphoma. 2012 Oct;53(10):1953-60. doi: 10.3109/10428194.2012.673226. Epub 2012 Apr 23.
|
| 12 |
Recurrent Cytogenetic Abnormalities in Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia.Methods Mol Biol. 2017;1541:279-293. doi: 10.1007/978-1-4939-6703-2_22.
|
| 13 |
A first time report on the coocurrence of sarcoidosis and ALK(-) CD30(+) anaplastic large cell lymphoma that is highly responsive to brentuximab vedotin treatment.J Oncol Pharm Pract. 2019 Oct;25(7):1801-1805. doi: 10.1177/1078155219837331. Epub 2019 Mar 25.
|
| 14 |
Deletion of cyclin-dependent kinase 4 inhibitor genes P15 and P16 in non-Hodgkin's lymphoma.Blood. 1995 Oct 15;86(8):2900-5.
|
| 15 |
Beta-2 microglobulin as a significant prognostic factor and a new risk model for patients with diffuse large B-cell lymphoma.Hematol Oncol. 2017 Dec;35(4):440-446. doi: 10.1002/hon.2312. Epub 2016 May 30.
|
| 16 |
SUMO-Modified FADD Recruits Cytosolic Drp1 and Caspase-10 to Mitochondria for Regulated Necrosis.Mol Cell Biol. 2017 Jan 4;37(2):e00254-16. doi: 10.1128/MCB.00254-16. Print 2017 Jan 15.
|
| 17 |
Gene-nutrient interactions among determinants of folate and one-carbon metabolism on the risk of non-Hodgkin lymphoma: NCI-SEER case-control study.Blood. 2007 Apr 1;109(7):3050-9. doi: 10.1182/blood-2006-07-034330.
|
| 18 |
Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells.Blood. 2019 May 16;133(20):2212-2221. doi: 10.1182/blood-2018-12-893396. Epub 2019 Feb 26.
|
| 19 |
PD1-CD28 Fusion Protein Enables CD4+ T Cell Help for Adoptive T Cell Therapy in Models of Pancreatic Cancer and Non-hodgkin Lymphoma.Front Immunol. 2018 Aug 30;9:1955. doi: 10.3389/fimmu.2018.01955. eCollection 2018.
|
| 20 |
Anti-CD47 Agent Boosts Macrophage Activity in NHL.Cancer Discov. 2019 Jan;9(1):7-8. doi: 10.1158/2159-8290.CD-NB2018-155. Epub 2018 Nov 21.
|
| 21 |
Anti-CD45 and anti-CD52 (Campath) monoclonal antibodies effectively eliminate systematically disseminated human non-Hodgkin's lymphoma B cells in Scid mice.Exp Hematol. 1996 Jul;24(8):919-26.
|
| 22 |
Harnessing a catalytic lysine residue for the one-step preparation of homogeneous antibody-drug conjugates.Nat Commun. 2017 Oct 24;8(1):1112. doi: 10.1038/s41467-017-01257-1.
|
| 23 |
Clock-cancer connection in non-Hodgkin's lymphoma: a genetic association study and pathway analysis of the circadian gene cryptochrome 2.Cancer Res. 2009 Apr 15;69(8):3605-13. doi: 10.1158/0008-5472.CAN-08-4572. Epub 2009 Mar 24.
|
| 24 |
DICE (dexamethasone, ifosfamide, cisplatin, etoposide) infusional chemotherapy for refractory or relapsed non-Hodgkin's lymphoma (NHL).Eur J Haematol Suppl. 2001 Jul;64:41-5.
|
| 25 |
Febrile neutropenia hospitalization due to pegfilgrastim on-body injector failure compared to single-injection pegfilgrastim and daily injections with reference and biosimilar filgrastim: US cost simulation for lung cancer and non-Hodgkin lymphoma.J Med Econ. 2020 Jan;23(1):28-36. doi: 10.1080/13696998.2019.1658591. Epub 2019 Sep 3.
|
| 26 |
G-CSF administration favours SDF-1 release and activation of neutrophils and monocytes in recipients of autologous peripheral blood progenitor cells.Cytokine. 2019 Apr;116:38-47. doi: 10.1016/j.cyto.2018.12.011. Epub 2019 Jan 24.
|
| 27 |
Silencing of DYRK2 increases cell proliferation but reverses CAM-DR in Non-Hodgkin's Lymphoma.Int J Biol Macromol. 2015 Nov;81:809-17. doi: 10.1016/j.ijbiomac.2015.08.067. Epub 2015 Sep 2.
|
| 28 |
CD64 surface expression on neutrophils and monocytes is significantly up-regulated after stimulation with granulocyte colony-stimulating factor during CHOP chemotherapy for patients with non-Hodgkin's lymphoma.Int J Hematol. 2004 Jan;79(1):55-62. doi: 10.1007/BF02983535.
|
| 29 |
The FCGR3A polymorphism predicts the response to rituximab-based therapy in patients with non-Hodgkin lymphoma: a meta-analysis.Ann Hematol. 2016 Sep;95(9):1483-90. doi: 10.1007/s00277-016-2723-x. Epub 2016 Jul 19.
|
| 30 |
Primary central nervous system diffuse large B-cell lymphoma shows an activated B-cell-like phenotype with co-expression of C-MYC, BCL-2, and BCL-6.Pathol Res Pract. 2017 Jun;213(6):659-665. doi: 10.1016/j.prp.2017.02.012. Epub 2017 Feb 24.
|
| 31 |
t(X;14)(p11;q32) in MALT lymphoma involving GPR34 reveals a role for GPR34 in tumor cell growth.Blood. 2012 Nov 8;120(19):3949-57. doi: 10.1182/blood-2011-11-389908. Epub 2012 Sep 10.
|
| 32 |
Variation in effects of non-Hodgkin lymphoma risk factors according to the human leukocyte antigen (HLA)-DRB1*01:01 allele and ancestral haplotype 8.1.PLoS One. 2011;6(11):e26949. doi: 10.1371/journal.pone.0026949. Epub 2011 Nov 9.
|
| 33 |
Intensive conventional-dose chemotherapy for stage IV low-grade lymphoma: high remission rates and reversion to negative of peripheral blood bcl-2 rearrangement.Ann Oncol. 1994;5 Suppl 2:73-7. doi: 10.1093/annonc/5.suppl_2.s73.
|
| 34 |
Prognostic value of microRNA 502 binding site SNP in the 3'-untranslated region of the SET8 gene in patients with non-Hodgkin's lymphoma.Tumori. 2014 Sep-Oct;100(5):553-8. doi: 10.1700/1660.18180.
|
| 35 |
ALK, the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkin's lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK).Oncogene. 1997 May 8;14(18):2175-88. doi: 10.1038/sj.onc.1201062.
|
| 36 |
Pan-class I PI3-kinase inhibitor BKM120 induces MEK1/2-dependent mitotic catastrophe in non-Hodgkin lymphoma leading to apoptosis or polyploidy determined by Bax/Bak and p53.Cell Death Dis. 2018 Mar 7;9(3):384. doi: 10.1038/s41419-018-0413-4.
|
| 37 |
The expression of CD30 in anaplastic large cell lymphoma is regulated by nucleophosmin-anaplastic lymphoma kinase-mediated JunB level in a cell type-specific manner.Cancer Res. 2006 Sep 15;66(18):9002-8. doi: 10.1158/0008-5472.CAN-05-4101.
|
| 38 |
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.Nat Biotechnol. 2016 Feb;34(2):155-63. doi: 10.1038/nbt.3391. Epub 2015 Nov 30.
|
| 39 |
5-Azacitidine induces demethylation of PTPL1 and inhibits growth in non-Hodgkin lymphoma.Int J Mol Med. 2015 Sep;36(3):698-704. doi: 10.3892/ijmm.2015.2269. Epub 2015 Jul 1.
|
| 40 |
Cell cycle and apoptosis regulatory protein (CARP)-1 is a novel, adriamycin-inducible, diffuse large B-cell lymphoma (DLBL) growth suppressor.Cancer Chemother Pharmacol. 2011 Jun;67(6):1401-13. doi: 10.1007/s00280-010-1442-6. Epub 2010 Aug 31.
|
| 41 |
Genetic variation of clock genes and cancer risk: a field synopsis and meta-analysis.Oncotarget. 2017 Apr 4;8(14):23978-23995. doi: 10.18632/oncotarget.15074.
|
| 42 |
Angioedema due to acquired C1-inhibitor deficiency: spectrum and treatment with C1-inhibitor concentrate.Orphanet J Rare Dis. 2019 Mar 13;14(1):65. doi: 10.1186/s13023-019-1043-3.
|
| 43 |
EBNA2 interferes with the germinal center phenotype by downregulating BCL6 and TCL1 in non-Hodgkin's lymphoma cells.J Virol. 2007 Mar;81(5):2274-82. doi: 10.1128/JVI.01822-06. Epub 2006 Dec 6.
|
| 44 |
The transferrin receptor part I: Biology and targeting with cytotoxic antibodies for the treatment of cancer.Clin Immunol. 2006 Nov;121(2):144-58. doi: 10.1016/j.clim.2006.06.010. Epub 2006 Aug 10.
|
| 45 |
TIGIT and PD-1 Mark Intratumoral T Cells with Reduced Effector Function in B-cell Non-Hodgkin Lymphoma.Cancer Immunol Res. 2019 Mar;7(3):355-362. doi: 10.1158/2326-6066.CIR-18-0351. Epub 2019 Jan 18.
|
| 46 |
A BAFF-R mutation associated with non-Hodgkin lymphoma alters TRAF recruitment and reveals new insights into BAFF-R signaling.J Exp Med. 2010 Nov 22;207(12):2569-79. doi: 10.1084/jem.20100857. Epub 2010 Nov 1.
|
| 47 |
The CD37-targeted antibody-drug conjugate IMGN529 is highly active against human CLL and in a novel CD37 transgenic murine leukemia model. Leukemia. 2014 Jul;28(7):1501-10.
|
| 48 |
Rare HVR1-HCV genotype 1b variants in patients with B non Hodgkin's lymphoma. Comparison with viral sequences detected in cases of lymphoproliferative disorders and B cell compartmentalisation.New Microbiol. 2007 Jul;30(3):265-70.
|
| 49 |
Association of Germline CHEK2 Gene Variants with Risk and Prognosis of Non-Hodgkin Lymphoma.PLoS One. 2015 Oct 27;10(10):e0140819. doi: 10.1371/journal.pone.0140819. eCollection 2015.
|
| 50 |
The +252A/G polymorphism in the Lymphotoxin- gene and the risk of non-Hodgkin lymphoma: a meta-analysis.Eur Rev Med Pharmacol Sci. 2014;18(4):544-52.
|
| 51 |
Preclinical Evaluation of Allogeneic CAR T Cells Targeting BCMA for the Treatment of Multiple Myeloma.Mol Ther. 2019 Jun 5;27(6):1126-1138. doi: 10.1016/j.ymthe.2019.04.001. Epub 2019 Apr 8.
|
| 52 |
Yttrium-90 ibritumomab tiuxetan (Zevalin) followed by BEAM (Z-BEAM) conditioning regimen and autologous stem cell transplantation (ASCT) in relapsed or refractory high-risk B-cell non-Hodgkin lymphoma (NHL): a single institution Italian experience.Ann Hematol. 2018 Sep;97(9):1619-1626. doi: 10.1007/s00277-018-3328-3. Epub 2018 Apr 16.
|
| 53 |
Genetic polymorphisms of biotransformation enzymes in patients with Hodgkin's and non-Hodgkin's lymphomas.Hum Mol Genet. 2001 Jun 1;10(12):1265-73. doi: 10.1093/hmg/10.12.1265.
|
| 54 |
Smoking, variation in N-acetyltransferase 1 (NAT1) and 2 (NAT2), and risk of non-Hodgkin lymphoma: a pooled analysis within the InterLymph consortium.Cancer Causes Control. 2013 Jan;24(1):125-34. doi: 10.1007/s10552-012-0098-4. Epub 2012 Nov 18.
|
| 55 |
Prolonged versus standard native E. coli asparaginase therapy in childhood acute lymphoblastic leukemia and non-Hodgkin lymphoma: final results of the EORTC-CLG randomized phase III trial 58951.Haematologica. 2017 Oct;102(10):1727-1738. doi: 10.3324/haematol.2017.165845. Epub 2017 Jul 27.
|
| 56 |
High levels of BACH2 associated with lower levels of BCL2 transcript abundance in t(14;18)(q21;q34) translocation positive non-Hodgkin's lymphoma.Leuk Res. 2009 May;33(5):731-4. doi: 10.1016/j.leukres.2008.09.007. Epub 2008 Oct 16.
|
| 57 |
Upregulation of ADAM12 contributes to accelerated cell proliferation and cell adhesion-mediated drug resistance (CAM-DR) in Non-Hodgkin's Lymphoma.Hematology. 2017 Oct;22(9):527-535. doi: 10.1080/10245332.2017.1312205. Epub 2017 Apr 10.
|
| 58 |
Mantle cell lymphoma - does primary intensive immunochemotherapy improve overall survival for younger patients?.Leuk Lymphoma. 2009 Aug;50(8):1249-56. doi: 10.1080/10428190903040030.
|
| 59 |
Expression of common fragile sites in untreated non-Hodgkin's lymphoma with aphidicolin and folate deficiency.Cancer Lett. 1994 Oct 28;86(1):111-7. doi: 10.1016/0304-3835(94)90187-2.
|
| 60 |
Frequent abnormalities of the p15 and p16 genes in mycosis fungoides and sezary syndrome.J Invest Dermatol. 2002 Mar;118(3):493-9. doi: 10.1046/j.0022-202x.2001.01682.x.
|
| 61 |
Perforin polymorphism A91V and susceptibility to B-precursor childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group. Leukemia. 2006 Sep;20(9):1539-41. doi: 10.1038/sj.leu.2404299. Epub 2006 Jun 22.
|
| 62 |
TRAF1 Signaling in Human Health and Disease.Front Immunol. 2018 Dec 18;9:2969. doi: 10.3389/fimmu.2018.02969. eCollection 2018.
|
| 63 |
Condensin mutations and abnormal chromosomal structures in pyothorax-associated lymphoma.Cancer Sci. 2007 Jul;98(7):1041-7. doi: 10.1111/j.1349-7006.2007.00500.x. Epub 2007 May 4.
|
| 64 |
HOXC4, HOXC5, and HOXC6 expression in non-Hodgkin's lymphoma: preferential expression of the HOXC5 gene in primary cutaneous anaplastic T-cell and oro-gastrointestinal tract mucosa-associated B-cell lymphomas.Blood. 1997 Nov 15;90(10):4116-25.
|
| 65 |
A miR-SNP of the KRT81 gene is associated with the prognosis of non-Hodgkin's lymphoma.Gene. 2014 Apr 15;539(2):198-202. doi: 10.1016/j.gene.2014.02.010. Epub 2014 Feb 12.
|
| 66 |
A polymorphism at the microRNA binding site in the 3' untranslated region of C14orf101 is associated with non-Hodgkin lymphoma overall survival.Cancer Genet. 2014 Apr;207(4):141-6. doi: 10.1016/j.cancergen.2014.03.007. Epub 2014 Mar 22.
|
| 67 |
BCL-6 gene mutations in posttransplantation lymphoproliferative disorders predict response to therapy and clinical outcome.Blood. 1998 Oct 1;92(7):2294-302.
|
| 68 |
Interactions within the MHC contribute to the genetic architecture of celiac disease.PLoS One. 2017 Mar 10;12(3):e0172826. doi: 10.1371/journal.pone.0172826. eCollection 2017.
|
| 69 |
Mechanisms of Regulated and Dysregulated CARD11 Signaling in Adaptive Immunity and Disease.Front Immunol. 2018 Sep 19;9:2105. doi: 10.3389/fimmu.2018.02105. eCollection 2018.
|
| 70 |
Deletion of 6q16-q21 in human lymphoid malignancies: a mapping and deletion analysis.Cancer Res. 2000 Jun 1;60(11):2775-9.
|
| 71 |
Association analysis between the Cdc6 G1321A polymorphism and the risk for non-Hodgkin lymphoma and hepatocellular carcinoma.Mutat Res. 2009 Mar 9;662(1-2):10-5. doi: 10.1016/j.mrfmmm.2008.11.014. Epub 2008 Dec 3.
|
| 72 |
Activation of a translocated human c-myc gene by an enhancer in the immunoglobulin heavy-chain locus.Nature. 1984 Jan 26-Feb 1;307(5949):334-40. doi: 10.1038/307334a0.
|
| 73 |
Characterization of two novel cell lines, DERL-2 (CD56+/CD3+/Tcry5+) and DERL-7 (CD56+/CD3-/TCRgammadelta-), derived from a single patient with CD56+ non-Hodgkin's lymphoma.Leukemia. 2001 Oct;15(10):1641-9. doi: 10.1038/sj.leu.2402239.
|
| 74 |
Role of DHX33 in c-Myc-induced cancers.Carcinogenesis. 2017 Jun 1;38(6):649-660. doi: 10.1093/carcin/bgx041.
|
| 75 |
Translation initiation complex eIF4F is a therapeutic target for dual mTOR kinase inhibitors in non-Hodgkin lymphoma.Oncotarget. 2015 Apr 20;6(11):9488-501. doi: 10.18632/oncotarget.3378.
|
| 76 |
Association between the ERCC2 Asp312Asn polymorphism and risk of cancer.Oncotarget. 2017 Jul 18;8(29):48488-48506. doi: 10.18632/oncotarget.17290.
|
| 77 |
Th1/Th2 cytokine expression and its relationship with tumor growth in B cell non-Hodgkin's lymphoma (NHL).Leuk Lymphoma. 2002 Jun;43(6):1313-21. doi: 10.1080/10428190290026385.
|
| 78 |
Polymorphism in the tumor necrosis factor-alpha promotor region and in the heat shock protein 70 genes associated with malignant tumors.Cancer. 1997 Oct 15;80(8):1489-96. doi: 10.1002/(sici)1097-0142(19971015)80:8<1489::aid-cncr17>3.0.co;2-1.
|
| 79 |
Serological identification of HSP105 as a novel non-Hodgkin lymphoma therapeutic target.Blood. 2011 Oct 20;118(16):4421-30. doi: 10.1182/blood-2011-06-364570. Epub 2011 Aug 22.
|
| 80 |
Genetic polymorphisms in IL10RA and TNF modify the association between blood transfusion and risk of non-Hodgkin lymphoma.Am J Hematol. 2012 Aug;87(8):766-9. doi: 10.1002/ajh.23244. Epub 2012 May 31.
|
| 81 |
ISL-1 is overexpressed in non-Hodgkin lymphoma and promotes lymphoma cell proliferation by forming a p-STAT3/p-c-Jun/ISL-1 complex.Mol Cancer. 2014 Jul 29;13:181. doi: 10.1186/1476-4598-13-181.
|
| 82 |
Galectin-7 in lymphoma: elevated expression in human lymphoid malignancies and decreased lymphoma dissemination by antisense strategies in experimental model.Cancer Res. 2007 Mar 15;67(6):2824-9. doi: 10.1158/0008-5472.CAN-06-3891.
|
| 83 |
Silencing of LIMD1 promotes proliferation and reverses cell adhesion-mediated drug resistance in non-Hodgkin's lymphoma.Oncol Lett. 2019 Mar;17(3):2993-3000. doi: 10.3892/ol.2019.9921. Epub 2019 Jan 11.
|
| 84 |
The Cancer Mutation D83V Induces an -Helix to -Strand Conformation Switch in MEF2B.J Mol Biol. 2018 Apr 13;430(8):1157-1172. doi: 10.1016/j.jmb.2018.02.012. Epub 2018 Feb 22.
|
| 85 |
Genetic variation in the NBS1, MRE11, RAD50 and BLM genes and susceptibility to non-Hodgkin lymphoma.BMC Med Genet. 2009 Nov 16;10:117. doi: 10.1186/1471-2350-10-117.
|
| 86 |
Haplotypic variation in MRE11, RAD50 and NBS1 and risk of non-Hodgkin's lymphoma.Leuk Lymphoma. 2006 Dec;47(12):2567-83. doi: 10.1080/10428190600909743.
|
| 87 |
Genetic polymorphisms in oxidative stress-related genes are associated with outcomes following treatment for aggressive B-cell non-Hodgkin lymphoma.Am J Hematol. 2014 Jun;89(6):639-45. doi: 10.1002/ajh.23709. Epub 2014 Apr 12.
|
| 88 |
Alteration of SMRT tumor suppressor function in transformed non-Hodgkin lymphomas.Cancer Res. 2005 Jun 1;65(11):4554-61. doi: 10.1158/0008-5472.CAN-04-4108.
|
| 89 |
Silencing NPAS2 promotes cell growth and invasion in DLD-1 cells and correlated with poor prognosis of colorectal cancer.Biochem Biophys Res Commun. 2014 Jul 25;450(2):1058-62. doi: 10.1016/j.bbrc.2014.06.104. Epub 2014 Jun 27.
|
| 90 |
Novel ORC4L gene mutation in B-cell lymphoproliferative disorders.Am J Med Sci. 2009 Dec;338(6):527-9. doi: 10.1097/MAJ.0b013e3181b7f17c.
|
| 91 |
Silencing of CKIP-1 promotes tumor proliferation and cell adhesion-mediated drug resistance via regulating AKT activity in non-Hodgkin's lymphoma.Oncol Rep. 2017 Jan;37(1):622-630. doi: 10.3892/or.2016.5233. Epub 2016 Nov 8.
|
| 92 |
PRRC2A and BCL2L11 gene variants influence risk of non-Hodgkin lymphoma: results from the InterLymph consortium.Blood. 2012 Nov 29;120(23):4645-8. doi: 10.1182/blood-2012-05-427989. Epub 2012 Oct 9.
|
| 93 |
Allelic variation of the c-raf-1 proto-oncogene in human lymphoma and leukemia.Oncogene. 1989 Apr;4(4):507-10.
|
| 94 |
miRNA-26b downregulation in peripheral blood mononuclear cells of patients with hepatitis C associated lymphomas is restored by successful interferon-free antiviral therapy.Antivir Ther. 2019;24(6):437-442. doi: 10.3851/IMP3322.
|
| 95 |
Retrospective identification of a previously undetected clinical case of OXA-48-producing K. pneumoniae and E. coli: the importance of adequate detection guidelines.Infection. 2016 Feb;44(1):107-10. doi: 10.1007/s15010-015-0805-7. Epub 2015 Jun 11.
|
| 96 |
SMARCAL1 deficiency predisposes to non-Hodgkin lymphoma and hypersensitivity to genotoxic agents in vivo.Am J Med Genet A. 2012 Sep;158A(9):2204-13. doi: 10.1002/ajmg.a.35532. Epub 2012 Aug 7.
|
| 97 |
Detection of membrane and soluble interleukin-6 receptor in lymphoid malignancies.Br J Haematol. 1995 Dec;91(4):871-7. doi: 10.1111/j.1365-2141.1995.tb05403.x.
|
| 98 |
Paediatric T-cell lymphoma of the appendix: a case report.Diagn Pathol. 2013 Jan 9;8:2. doi: 10.1186/1746-1596-8-2.
|
| 99 |
Association between lymphoma prognosis and aberrant methylation of ID4 and ZO-1 in bone marrow and paraffin-embedded lymphoma tissues of treatment-naive patients.Oncol Rep. 2013 Jul;30(1):455-61. doi: 10.3892/or.2013.2450. Epub 2013 May 10.
|
| 100 |
Tumor necrosis factor- induced protein 8 polymorphism and risk of non-Hodgkin's lymphoma in a Chinese population: a case-control study.PLoS One. 2012;7(5):e37846. doi: 10.1371/journal.pone.0037846. Epub 2012 May 29.
|
| 101 |
Leukocyte Ig-Like receptor B1 restrains dendritic cell function through increased expression of the NF-B regulator ABIN1/TNIP1.J Leukoc Biol. 2016 Oct;100(4):737-746. doi: 10.1189/jlb.1A0915-420RRR. Epub 2016 Apr 29.
|
| 102 |
TP73, an under-appreciated player in non-Hodgkin lymphoma pathogenesis and management.Curr Mol Med. 2014 May;14(4):432-9. doi: 10.2174/1566524014666140414204458.
|
| 103 |
Mutation of bcl-x gene in non-Hodgkin's lymphoma.Am J Hematol. 2002 Jan;69(1):74-6. doi: 10.1002/ajh.10030.
|
| 104 |
SHMT1 C1420T polymorphism contributes to the risk of non-Hodgkin lymphoma: evidence from 7309 patients.Chin J Cancer. 2015 Dec 14;34(12):573-82. doi: 10.1186/s40880-015-0065-z.
|
|
|
|
|
|
|
